Fly News Breaks for February 27, 2020
Feb 27, 2020 | 06:58 EDT
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Anavex with an Overweight rating and $11 price target. Anavex's first-in-class sigma 1 receptor agonist platform leverages a novel drug target with a differentiating mechanism of action to reduce inflammation and activation of cellular stress responses that are increasingly being seen as hallmarks of many neurodevelopmental and degenerative diseases, Duncan tells investors in a research note. He adds that the company's lead candidate ANAVEX 2-73 is currently being evaluated in several indications, including Rett syndrome, Parkinson's disease dementia and early Alzheimer's disease.
News For AVXL From the Last 2 Days
There are no results for your query AVXL